Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2022

14.01.2022 | short review

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

verfasst von: Johannes Schöche, Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Agents targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) are part of systemic therapy in advanced colorectal cancer. It is well known that only certain molecular subpopulations profit from EGFR antibodies, restricting those therapeutics to a smaller fraction of patients. Recently investigated, the monitoring of temporally changing RAS mutational status by liquid biopsy might allow the application of EGFR antibodies to an additional subset of patients. In addition, KRAS G12C inhibitors combined with anti-EGFR antibodies are currently under investigation in clinical trials and could provide another effective therapy in case of KRAS G12C mutations. Beyond RAS, therapy guided by microsatellite instability (MSI) status, BRAF mutations, HER2 overexpression and NTRK fusions are welcome additions to targeted treatment in advanced colorectal cancer.
Fußnoten
1
In the following, under the generalized term “RAS mutated”, named mutations will be subsided.
 
Literatur
6.
Zurück zum Zitat Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K‑ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65. CrossRefPubMed Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K‑ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65. CrossRefPubMed
7.
Zurück zum Zitat van Cutsem E, Köhne C‑H, Hitre E, Zaluski J, Chang Chien C‑R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. CrossRefPubMed van Cutsem E, Köhne C‑H, Hitre E, Zaluski J, Chang Chien C‑R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. CrossRefPubMed
8.
Zurück zum Zitat de Roock W, Claes B, Bernasconi D, de Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62. CrossRefPubMed de Roock W, Claes B, Bernasconi D, de Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62. CrossRefPubMed
9.
Zurück zum Zitat Douillard J‑Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34. CrossRefPubMed Douillard J‑Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34. CrossRefPubMed
10.
Zurück zum Zitat Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888. CrossRefPubMedPubMedCentral Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888. CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Pietrantonio F, Petrelli F, Coinu A, di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–94. CrossRefPubMed Pietrantonio F, Petrelli F, Coinu A, di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–94. CrossRefPubMed
14.
Zurück zum Zitat Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res. 2019;25(23):6899. CrossRefPubMedPubMedCentral Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res. 2019;25(23):6899. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Arnold D, Lueza B, Douillard J‑Y, Peeters M, Lenz H‑J, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713. CrossRefPubMedPubMedCentral Arnold D, Lueza B, Douillard J‑Y, Peeters M, Lenz H‑J, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713. CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat André T, Shiu K‑K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18. CrossRefPubMed André T, Shiu K‑K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18. CrossRefPubMed
19.
Zurück zum Zitat Cremolini C, Rossini D, Antoniotti C, Pietrantonio F, Lonardi S, Salvatore L, et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol. 2021;32:S1294–S5. https://​doi.​org/​10.​1016/​j.​annonc.​2021.​08.​2094. CrossRef Cremolini C, Rossini D, Antoniotti C, Pietrantonio F, Lonardi S, Salvatore L, et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol. 2021;32:S1294–S5. https://​doi.​org/​10.​1016/​j.​annonc.​2021.​08.​2094. CrossRef
22.
Zurück zum Zitat Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://​doi.​org/​10.​1016/​S1470-2045(16)00150-9. CrossRefPubMed Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://​doi.​org/​10.​1016/​S1470-2045(16)00150-9. CrossRefPubMed
26.
Zurück zum Zitat Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40. CrossRefPubMedPubMedCentral Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40. CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40. CrossRefPubMedPubMedCentral Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801. CrossRefPubMedPubMedCentral Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801. CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53. CrossRefPubMed Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53. CrossRefPubMed
30.
Zurück zum Zitat Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50. CrossRefPubMed Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50. CrossRefPubMed
33.
Zurück zum Zitat Arnold D, Prager GW, Quintela A, Stein A, Vera SM, Mounedji N, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29:835–56. CrossRefPubMedPubMedCentral Arnold D, Prager GW, Quintela A, Stein A, Vera SM, Mounedji N, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29:835–56. CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Henry J, Willis J, Parseghian CM, Raghav KPS, Johnson B, Dasari A, et al. NeoRAS: incidence of RAS reversion from RAS mutated to RAS wild type. J Clin Oncol. 2020;38(4_suppl):180. CrossRef Henry J, Willis J, Parseghian CM, Raghav KPS, Johnson B, Dasari A, et al. NeoRAS: incidence of RAS reversion from RAS mutated to RAS wild type. J Clin Oncol. 2020;38(4_suppl):180. CrossRef
36.
Zurück zum Zitat Sunakawa Y, Usher J, Satake H, Jaimes Y, Miyamoto Y, Nakamura M, et al. Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation. Ann Oncol. 2018;29:viii181–viii2. CrossRef Sunakawa Y, Usher J, Satake H, Jaimes Y, Miyamoto Y, Nakamura M, et al. Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation. Ann Oncol. 2018;29:viii181–viii2. CrossRef
37.
Zurück zum Zitat Osumi H, Vecchione L, Keilholz U, Vollbrecht C, Alig AHS, von Einem JC, et al. NeoRAS wild-type in metastatic colorectal cancer: myth or truth?—Case series and review of the literature. Eur J Cancer. 2021;153:86–95. CrossRefPubMed Osumi H, Vecchione L, Keilholz U, Vollbrecht C, Alig AHS, von Einem JC, et al. NeoRAS wild-type in metastatic colorectal cancer: myth or truth?—Case series and review of the literature. Eur J Cancer. 2021;153:86–95. CrossRefPubMed
39.
Zurück zum Zitat Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. Cancer Discov. 2020;10:1129–68. CrossRefPubMedPubMedCentral Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. Cancer Discov. 2020;10:1129–68. CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, et al. KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population. Clin Colorectal Cancer. 2020;19(3):219–25. CrossRefPubMed Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, et al. KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population. Clin Colorectal Cancer. 2020;19(3):219–25. CrossRefPubMed
44.
Zurück zum Zitat Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310. CrossRefPubMed Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310. CrossRefPubMed
Metadaten
Titel
Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations
verfasst von
Johannes Schöche
Dora Niedersüß-Beke
Publikationsdatum
14.01.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00787-1